Increasing evidence suggests that PPARγ activity is attenuated during the transition from adenoma to adenocarcinoma, likely explaining why PPARγ agonists are effective in blocking the early stages of tumorigenesis while no effect is detected in advanced tumor stages [39, 40]. The gene discussed is PPARG; the disease is neoplasm.